Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2003

View Archived Issues

New progesterone receptor modulators under investigation at Akzo Nobel

New prostanoid EP1 modulators in early development at GSK

Tropane-based chemokine CCR5 modulators newly developed at Pfizer

Sanofi-Synthelabo presents new bFGF antagonists for cancer and other disorders

Tanabe Seiyaku scientists design novel factor Xa inhibitors

Novel alpha4 integrin antagonists and their use reported by Uriach team

BMS researchers design novel IKK inhibitors for inflammatory and immune disorders

Aventis Pharma scientists design new glycogen phosphorylase inhibitors

Enrollment completed in final phase III trial for Entereg in postoperative ileus

Idec and Biogen complete merger

Toxicity studies for Inosine to pave way for IND filing

ECOG phase III trial of Rituxan reaches primary efficacy endpoint early

HIVA.MVA trials commence in South Africa and Switzerland

Abbott transfers joint diabetes collaboration rights to Karo Bio

Protocol finalized for Mycograb trial

Plexxikon research supports drug discovery for phosphodiesterase targets

Predix and RRD team up to expedite development of PRX-00023

New review date set for Estorra NDA

4SC and Switch Biotech enter dermatological drug discovery partnership

Tanox and Wyeth enter osteoporosis development agreement

TopoTarget initiates phase I U.K. study of PXD-101

ViaCell acquires Kourion Therapeutics

Silver-based antimicrobial agent may help prevent the spread of SARS

Kissei preparing to license two of its products

LY-156735 is safe and well tolerated in healthy volunteers

Focus on drug therapy for autism

Improved quality of life found with CTLA4Ig and methotrexate in RA patients

Therapeutic benefits of intraurethral botulinum toxin type A in urinary tract dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...